Consensus Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.91 ^USD	+0.82%		-1.60%	-45.38%

Mar. 20	ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	CI
Mar. 07	Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Aurinia Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

990f.wwTkdJKg4_y_k4sG_hOwBByWnJO0_H4Y51fLv9Sd50Q.7ja7GsbTqZuO8PlZmXjHbmnRxdKFlTIgrBqE7IT8lTyqKZdE6PPTht3Q-A~6451b60f1227713ebe066562776cce6b

Analyst Recommendations on Aurinia Pharmaceuticals Inc.

HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	Feb. 22	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	Feb. 16	MT
HC Wainwright Adjusts Price Target on Aurinia Pharmaceuticals to $15 From $14, Maintains Buy Rating	23-08-07	MT
RBC Boosts Price Target on Aurinia Pharmaceuticals to $13 From $11 Ahead of Q1 Report, Keeps Outperform, Speculative Risk	23-05-02	MT
HC Wainwright Adjusts Price Target on Aurinia Pharmaceuticals to $14 From $26, Maintains Buy Rating	22-11-07	MT
SVB Securities Adjusts Price Target on Aurinia Pharmaceuticals to $12 From $17, Maintains Outperform Rating	22-11-04	MT
Oppenheimer Downgrades Aurinia Pharmaceuticals to Perform From Outperform, Notes Continued Commercial Challenges	22-11-04	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $10 From $18, Maintains Outperform, Speculative Risk Rating	22-11-04	MT
US Futures Lower Following Rate Hike, Ahead of Jobless, PMI Data	22-11-03	MT
HC Wainwright Adjusts Aurinia Pharmaceuticals' Price Target to $26 from $30, Keeps Buy Rating	22-08-09	MT
SVB Financial Adjusts Aurinia Pharmaceuticals Price Target to $17 From $22, Maintains Outperform Rating	22-08-08	MT
Oppenheimer Adjusts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Outperform Rating	22-08-05	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $18 From $22, Citing Potential Scenarios for '036 Patent; Outperform, Speculative Risk Kept	22-08-05	MT
Cantor Fitzgerald Assumes Aurinia Pharmaceuticals at Overweight with $25 Price Target	22-05-05	MT
HC Wainwright Adjusts Price Target on Aurinia Pharmaceuticals to $30 From $33, Reiterates Buy Rating	22-05-05	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $22 From $27, Maintains Outperform Rating, Speculative Risk Qualifier	22-04-28	MT
SVB Leerink Adjusts Aurinia Pharmaceuticals' Price Target to $22 from $30, Keeps Outperform Rating	22-03-08	MT
Oppenheimer Adjusts Aurinia Pharmaceuticals Price Target to $18 From $31, Maintains Outperform Rating	22-03-02	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $27 From $31, Maintains Outperform Rating With Speculative Risk Qualifier	22-03-01	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $31 From $34, Maintains Outperform-Speculative Risk Rating	22-02-23	MT
Oppenheimer Upgrades Aurinia Pharmaceuticals to Outperform From Perform, Adjusts PT to $31 From $33	21-12-10	MT
SVB Leerink Adjusts Aurinia Pharmaceuticals' Price Target to $35 from $28, Keeps Outperform Rating	21-11-04	MT
HC Wainwright Adjusts Aurinia Pharmaceuticals' Price Target to $40 from $35, Keeps Buy Rating	21-11-04	MT
Oppenheimer Downgrades Aurinia Pharmaceuticals to Perform from Outperform, Adjusts Price Target to $32 from $28	21-10-28	MT
RBC Boosts Price Target on Aurinia Pharmaceuticals to $34 From $23 Amid Deal Chatter; Outperform, Speculative Risk Kept	21-10-26	MT